Analyst Price Targets — CNMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 2:09 pm | — | Wells Fargo | $39.00 | $41.98 | TheFly | Wells finds Conmed sale report 'little surprising' after refinance |
| July 8, 2026 8:30 pm | — | BMO Capital | $36.00 | $33.59 | TheFly | Conmed initiated with a Market Perform at BMO Capital |
| May 1, 2025 1:26 pm | Mike Matson | Needham | $61.00 | $57.19 | TheFly | Conmed price target lowered to $61 from $91 at Needham |
| October 4, 2024 9:04 am | Mike Matson | Needham | $97.00 | $66.59 | StreetInsider | Needham Reiterates Buy Rating on CONMED (CNMD) |
| April 25, 2024 9:46 am | Matt O\'Brien | Piper Sandler | $95.00 | $64.34 | StreetInsider | CONMED (CNMD) PT Lowered to $95 at Piper Sandler |
| April 25, 2024 7:28 am | Mike Matson | Needham | $107.00 | $70.01 | StreetInsider | CONMED (CNMD) PT Lowered to $107 at Needham |
| October 26, 2022 8:00 pm | Matt O'Brien | Piper Sandler | $108.00 | $83.39 | TheFly | Conmed price target lowered to $108 from $118 at Piper Sandler |
Latest News for CNMD
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number…
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (“CFO”), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. “We are pleased to welcome a talented and experienced financial executive of John's caliber to CONMED,” said Patrick J. Beyer,…
CNMD is sharpening its focus on AirSeal, Buffalo Filter and BioBrace, betting on higher-growth platforms to drive margin gains and long-term growth.
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CNMD.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.